Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)

This study evaluates the overall survival and disease free survival of melanoma patients that were treated with an autologous melanoma cell vaccine, administered as a post-operative adjuvant. Included are 43 patients with totally resected metastatic melanoma (28-AJCC stage III, 15-AJCC stage IV), wi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lotem, M, Peretz, T, Drize, O, Gimmon, Z, EL, D Ad, Weitzen, R, Goldberg, H, David, I Ben, Prus, D, Hamburger, T, Shiloni, E
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 2002
Subjects:	Clinical
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2746603/ https://ncbi.nlm.nih.gov/pubmed/12085200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600251
Tags:	Add Tag No Tags, Be the first to tag this record!

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)

Similar Items